fbpixel

High Cholesterol research studies for holistic treatments

Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after high-cholesterol treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of high-cholesterol and related therapies
as they heal people who benefited from our expertise.

See: How to lower cholesterol naturally

/ title=”Morelloflavone from Garcinia dulcis as a novel biflavonoid inhibitor of HMG-CoA reductase.”>
Morelloflavone from Garcinia dulcis as a novel biflavonoid inhibitor of HMG-CoA reductase.

February 2011

Morelloflavone, a biflavonoid from Garcinia dulcis previously shown to have hypocholesterolemic activity, was examined for its effect on HMG-CoA reductase, the rate-limiting enzyme of the cholesterol biosynthetic pathway. By using the catalytic domain of house mouse HMG-CoA reductase, morelloflavone was found to inhibit the enzyme activity by competing with HMG-CoA whereas it was non-competitive towards NADPH. The inhibition constants (K(i)) with respect to HMG-CoA and NADPH were 80.87± 0.06 µm and 103 ± 0.07 µm, respectively. Both flavonoid subunits of this compound, naringenin and luteolin, equally competed with HMG-CoA with K(i) of 83.58 ± 4.37 µm and 83.59 ± 0.94 µm, respectively, and were also non-competitive with NADPH (K(i) of 182 ± 0.67 µm and 188 ± 0.14 µm, respectively). Due to these findings, we suggest that each subunit of morelloflavone would occupy the active site of the enzyme, thereby blocking access of its substrate. The present study thus demonstrates the ability of morelloflavone from G. dulcis to inhibit HMG-CoA reductase in vitro. As a result, this biflavonoid might serve as a new candidate for the future development of hypocholesterolemic agents.

/ onclick=”MoreLine(‘11577’, ‘Morelloflavone from Garcinia dulcis as a novel biflavonoid inhibitor of HMG-CoA reductase.’)”>
…more

/ title=”Meta-analysis of the effects of flaxseed interventions on blood lipids.”>
Meta-analysis of the effects of flaxseed interventions on blood lipids.

August 2009

Background:
Several clinical trials have investigated the effects of flaxseed and flaxseed-derived products (flaxseed oil or lignans) on blood lipids; however, the findings have been inconsistent. OBJECTIVE:
We aimed to identify and quantify the effectiveness of flaxseed and its derivatives on blood lipid profiles.
DESIGN:
A comprehensive literature search was performed on the basis of English reports of randomized controlled trials of flaxseed or its derivatives on lipid profiles in adults, which were published from January 1990 to October 2008. Attempts also were made to access unpublished data. Study quality was assessed by using the Jadad score, and a meta-analysis was conducted.
Results:
Twenty-eight studies were included. Flaxseed interventions reduced total and LDL cholesterol by 0.10 mmol/L (95% CI: -0.20, 0.00 mmol/L) and 0.08 mmol/L (95% CI: -0.16, 0.00 mmol/L), respectively; significant reductions were observed with whole flaxseed (-0.21 and -0.16 mmol/L, respectively) and lignan (-0.28 and -0.16 mmol/L, respectively) supplements but not with flaxseed oil. The cholesterol-lowering effects were more apparent in females (particularly postmenopausal women), individuals with high initial cholesterol concentrations, and studies with higher Jadad scores. No significant changes were found in the concentrations of HDL cholesterol and triglycerides. CONCLUSIONS: Flaxseed significantly reduced circulating total and LDL-cholesterol concentrations, but the changes were dependent on the type of intervention, sex, and initial lipid profiles of the subjects. Further studies are needed to determine the efficiency of flaxseed on lipid profiles in men and premenopausal women and to explore its potential benefits on other cardiometabolic risk factors and prevention of cardiovascular .

/ onclick=”MoreLine(‘11563’, ‘Meta-analysis of the effects of flaxseed interventions on blood lipids.’)”>
…more

/ title=”Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans.”>
Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans.

January 2011

Studies in vitro and in mice indicate a role for Coenzyme Q(10) (CoQ(10) ) in gene expression. To determine this function in relationship to physiological readouts, a 2-week supplementation study with the reduced form of CoQ(10) (ubiquinol, Q(10) H(2) , 150 mg/d) was performed in 53 healthy males. Mean CoQ(10) plasma levels increased 4.8-fold after supplementation. Transcriptomic and bioinformatic approaches identified a gene-gene interaction network in CD14-positive monocytes, which functions in inflammation, cell differentiation, and peroxisome proliferator-activated receptor-signaling. These Q(10) H(2) -induced gene expression signatures were also described previously in liver tissues of SAMP1 mice. Biochemical and NMR-based analyses showed a reduction of low density lipoprotein (LDL) cholesterol plasma levels after Q(10) H(2) supplementation. This effect was especially pronounced in atherogenic small dense LDL particles (19-21 nm, 1.045 g/L). In agreement with gene expression signatures, Q(10) H(2) reduces the number of erythrocytes but increases the concentration of reticulocytes. In conclusion, Q(10) H(2) induces characteristic gene expression patterns, which are translated into reduced LDL cholesterol levels and altered parameters of erythropoiesis in humans.

/ onclick=”MoreLine(‘11559’, ‘Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans.’)”>
…more

/ title=”[The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hypercholesterolemia].”>
[The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hypercholesterolemia].

October 2005

THE AIM OF THE STUDY: Our investigations was to estimate the influence of Aronia anthocyanins (Aronox by Agropharm) on selected parameters of oxidative and antioxidative balance as well as on the concentration of selected metals in red blood cells in men with hipercholesterolaemia. MATERIAL AND
METHODS:
16 men aged 27 +/- 6.4 years old with blood cholesterol concentration on the level of 205-250 mg/dl took 240 mg of anthocyanins a day for 30 days. Before and after the period of anthocyanins administration a blood sample was taken and following parameters were estimated: lead, aluminium, cooper and zinc concentration in erythrocytes with the method of atomic emission spectrometry with induced coupling plasma (AES-ICP), concentration of substances reacting with thiobarbituric acid (TBARS) and superoxide dismutase, glutathione peroxidase and catalase activities in hemolysate.
Conclusion:
30 days long administration of 240 mg of anthocyanins a day, caused a substantial increase of glutathione peroxidase and catalase activities. The lead, aluminium and cooper concentration was decreased while zinc concentration in red blood cells was increased.

/ onclick=”MoreLine(‘11539’, ‘[The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hypercholesterolemia].’)”>
…more

/ title=”Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion.”>
Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion.

October 2010

AIM: Present study aimed to elucidate the suppression of serum lipids by gamma- and delta-tocotrienol (??T3).
METHODS:
The lipid-lowering effects of??T3 were investigated using HepG2 liver cell line, hypercholesterolemic mice and borderline-high cholesterol patients.
Results:
In-vitro results demonstrated two modes of action. First,??T3 suppressed the upstream regulators of lipid homeostasis genes (DGAT2, APOB100, SREBP1/2 and HMGCR) leading to the suppression of triglycerides, cholesterol and VLDL biosyntheses. Second, ??T3 enhanced LDL efflux through induction of LDL receptor (LDLr) expression. Treatment of LDLr-deficient mice with 1 mg/day (50 mg/kg/day) ??T3 for one-month showed 28%, 19% reduction in cholesterol and triglyceride levels respectively, whereas HDL level was unaltered. The lipid-lowering effects were not affected by alpha-tocopherol (?TP). In a placebo-controlled human trial using 120 mg/day ??T3, only serum triglycerides were lowered by 28% followed by concomitant reduction in the triglyceride-rich VLDL and chylomicrons. In contrast, total cholesterol, LDL and HDL remained unchanged in treated and placebo groups. The discrepancies between in-vitro, in-vivo and human studies may be attributed to the differential rates of post-absorptive ??T3 degradation and LDL metabolism.
Conclusion:
Reduction in triglycerides synthesis and transport may be the primary benefit caused by ingesting??T3 in human.

/ onclick=”MoreLine(‘11523’, ‘Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion.’)”>
…more

/ title=”Physicochemical properties of oat?-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial.”>
Physicochemical properties of oat?-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial.

October 2010

Background:
Consumption of 3 g oat?-glucan/d is considered sufficient to lower serum LDL cholesterol, but some studies have shown no effect. LDL cholesterol lowering by oat ?-glucan may depend on viscosity, which is controlled by the molecular weight (MW) and amount of oat ?-glucan solubilized in the intestine (C). OBJECTIVES:
Our 2 primary objectives were to determine whether consumption of 3 g high-MW oat ?-glucan/d would reduce LDL cholesterol and whether LDL cholesterol lowering was related to the log(MW × C) of oat ?-glucan.
DESIGN:
In a double-blind, parallel-design, multicenter clinical trial, subjects with LDL cholesterol ?3.0 and ?5.0 mmol/L (n = 786 screened, n = 400 ineligible, n = 19 refused, n = 367 enrolled, and n = 345 completed) were randomly assigned to receive cereal containing wheat fiber (n = 87) or 3 g high-MW (2,210,000 g/mol, n = 86), 4 g medium-MW (850,000 g/mol, n = 67), 3 g medium-MW (530,000 g/mol, n = 64), or 4 g low-MW (210,000 g/mol, n = 63) oat ?-glucan/d (divided doses, twice daily) for 4 wk.
Results:
LDL cholesterol was significantly less with 3 g high-MW, 4 g medium-MW, and 3 g medium-MW oat ?-glucan cereals than with the wheat-fiber cereal by 0.21 (5.5%; 95% CI: -0.11,-0.30; P = 0.002), 0.26 (6.5%; 95% CI: -0.14, -0.37; P = 0.0007), and 0.19 (4.7%; 95% CI: -0.08, -0.30; P = 0.01) mmol/L, respectively. However, the effect of 4 g low-MW oat ?-glucan/d (0.10 mmol/L) was not significant (2.3%; 95% CI: 0.02, -0.20). By analysis of covariance, log(MW × C) was a significant determinant of LDL cholesterol (P = 0.003). Treatment effects were not significantly influenced by age, sex, study center, or baseline LDL cholesterol. CONCLUSIONS: The physicochemical properties of oat ?-glucan should be considered when assessing the cholesterol-lowering ability of oat-containing products; an extruded breakfast cereal containing 3 g oat ?-glucan/d with a high-MW (2,210,000 g/mol) or a medium-MW (530,000 g/mol) lowered LDL cholesterol similarly by ?0.2 mmol/L (5%), but efficacy was reduced by 50% when MW was reduced to 210,000 g/mol. This trial was registered at www.clinicaltrials.gov as NCT00981981.

/ onclick=”MoreLine(‘11504’, ‘Physicochemical properties of oat?-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial.’)”>
…more

Have a Question?